Novavax, Inc. (NASDAQ:NVAX) Updates Piper Jaffray
Novavax, Inc. (NASDAQ:NVAX) is a $1 billion market capped clinical stage drug maker which has its HQ in Rockville, Maryland. The stock of this drug maker has been on the move in the closing weeks of last month and posted strong gains at the stock market. The spurt in the valuation of the stock happened in the back drop of a sales pitch that its top executives provided at the Piper Jaffray HC 2013 Conference in early December.
Executives Presented At Piper Jaffray Investor Meet
Novavax, Inc. (NASDAQ:NVAX) President and CEO Stanley C Erck along with Dr. Gregory M Glenn, who is Chief Medical Officer Novavax, Inc. (NASDAQ:NVAX) took pains to explain the limitless potential of their novel approach to drug design. Their approach involves using identified proteins which fight viruses and linking them with the recombinant system that the company has developed. This approach is a mirror of the defensive system that Novavax, Inc. (NASDAQ:NVAX) researchers had observed in a bugs which successfully fought a virus called Baculovirus.
Taking Inspiration from a Bug for a Drug
Throwing light on the approach his development team is taking in the development of this novel treatment approach, Dr. Greg Glenn, Chief Scientific Officer at Novavax, Inc. (NASDAQ:NVAX) has been quoted to have explained, “ So a Baculovirus is a virus that infects all bugs. The Baculovirus has been adapted for an insect cell that is an army of [overly] cell that is an immortalized cell. So we put the gene in the back of ours and infects the insect cell and outcome is the protein of interest, usually a vaccine. So we make two end particles, a virus side particle, or a nanoparticle. And the virus like particle looks like a virus, it has a structure like the flu for example has hem agglutinin and neuraminidase on the outside and that looks to the immune system like a virus.”
Novavax, Inc. (NASDAQ:NVAX) head honchos believe that their team is on the verge of validating this approach to cure diseases and have boldly predicted that this year will witness the company going ahead and successfully getting FDA approval for its unique treatment approach.